ReACT Therapeutics

🎬 CHECK OUT OUR NEW VIDEO! 🎬 We are on a mission to address the urgent needs of patients facing treatment failure by targeting Multi-Drug Resistance (MDR) phenomena in oncology. Clinical data reveals that a staggering 90% of deaths during anticancer treatment are linked to MDR. That's why we are specifically focusing on combating the efflux of anticancer drugs through the Breast Cancer Resistance Protein (BCRP), which is expressed in various cancer types, including 9 out of the 10 most prevalent cancers worldwide. It's a critical challenge that currently lacks an effective solution. After over 15 years of tireless academic research, we've developed highly innovative BCRP inhibitors that are protected by robust intellectual property rights in key global markets. Our lead molecule, ValOMé, represents the cutting-edge fifth generation of BCRP inhibitors, surpassing previous versions in terms of safety, selectivity, and efficacy.  But that's not all - ValOMé has the potential to be combined with existing and future anticancer drugs, revolutionizing treatment options for patients. In fact, we have identified 40 anticancer drugs effluxed by BCRP, utilized for 14 indications across chemotherapy, targeted therapy, hormone therapy, and even antibody-drug conjugates. The potential impact of our technology is immense. By leveraging our novel chemical entities' remarkable selectivity for BCRP, ReACT Therapeutics has the power to significantly improve remission rates and enhance the quality of life for countless patients. Our initial preclinical developments have already demonstrated the safety and efficacy of ValOMé. Now, we're thrilled to embark on the next phase of our journey. Over the next three years, we're fully committed to completing the preclinical phase and regulatory affairs, paving the way for groundbreaking clinical trials ➡️ Join us on this exhilarating path as we revolutionize the fight against MDR in oncology. Together, we can make a resounding difference and reshape the future of cancer treatment. Stay tuned for more updates as we forge ahead towards our shared vision of better health for all. Bpifrance, Linksium, Lyonbiopôle, Cancéropôle Lyon Auvergne-Rhône-Alpes, CHU Grenoble Alpes, Centre Léon Bérard, Hospices Civils de Lyon, Université Grenoble Alpes, CNRS - Centre national de la recherche scientifique, Région Auvergne-Rhône-Alpes #ReACTTherapeutics #BiotechStartup #Oncology #MDR #Innovation #CancerTreatment #Research #ClinicalTrials

Excited to be part of this Lyonbiopôle Auvergne-Rhône-Alpes event! Looking forward to the opportunities and connections ahead.

📣 Le Paris Saclay Cancer Cluster (PSCC) publie un guide pratique intitulé « Pourquoi et comment travailler avec des patients » à destination des startups Healthtech en oncologie. Ce guide, élaboré par un groupe de travail composé de membres du comité des patients du PCSS, fournit des informations essentielles sur les rôles, missions et compétences des patients partenaires. 💬 Découvrez également les témoignages inspirants de startups collaborant déjà avec des patients, notamment Healshape, Prostperia et ReACT Therapeutics. ✅ ReACT Therapeutics, dès sa création, a intégré dans son comité scientifique Cyril Sarrauste de Menthiere, co-responsable de Mon Réseau Cancer Colorectal (Patients en Réseau) et membre du Bureau de Digestive Cancers Europe. La technologie développée par ReACT Therapeutics vise à améliorer l’efficacité de 40 médicaments anticancéreux, utilisés pour traiter 14 types de cancers différents. Travailler à la fois pour et avec les patients est crucial pour atteindre cet objectif ambitieux. 👉 En exploitant pleinement notre technologie, nous pouvons significativement augmenter les chances de rémission et la qualité de vie de milliers, voire de millions de personnes chaque année. Ensemble, innovons pour transformer et améliorer la vie des patients. #ReactTherapeutics #PSCC #Biotech #Medtech #Healthtech #Oncology #startup #PatientPartenaire #Innovation #Cancer #Collaboration #PatientEngagement

ReACT Therapeutics is thrilled to announce our nomination for the Trophée Jeune entreprise de France Biotech! Last Thursday, our CEO, Emile Roussel, PhD, took the stage to pitch our vision, team, and groundbreaking technology in front of the esteemed jury, co-chaired by Lise ALTER and Audrey Derveloy. It was a nerve-wracking but exhilarating 3 minutes as we laid out our passion and dedication to revolutionize and redefine the way we approach cancer treatment. The name of the winner will be announced on March 25th at 6:00 PM during a ceremony. Let's keep our fingers crossed for ReACT Therapeutics! 🤞 #ReACTTherapeutics #BiotechInnovation #StartupNomination #Entrepreneurship #HealthcareInnovation #PitchingSuccess #AwardNominee #CancerTreatment #IndustryLeadership #BusinessAchievement #InnovateWithPassion #ExcitingNews #FutureOfHealthcare #TrophéeJeuneEntreprise #FranceBiotech

Last Thursday, our CEO, Emile Roussel, PhD Roussel, had the opportunity to pitch the innovative project of ReACT Therapeutics to members of the Savoie Mont Blanc Angels - SAMBA business angels network. It was an insightful and productive session, and we're grateful for the chance to share our vision for the future of biotech with such a distinguished audience. 🌐 https://lnkd.in/euuaGKhJ ➡️ contact@react-therapeutics.com #biotech #innovation #startup #entrepreneurship #pitch #businessangels #networking #healthcare #pharmaceuticals #investing #science #technology #research #startuplife #CEO #leadership #entrepreneurs #evenement #hautesavoie #investissement #partenaire #investisseur #pitch

ReACT Therapeutics has been selected to participate in the Roche Diagnostics France 2024 mentoring program! This is an exceptional opportunity for us to be supported by a team of dedicated experts, ready to assist us in overcoming the challenges that ReACT Therapeutics aims to conquer. We would like to express our deep gratitude to the teams at MEDICALPS and Roche Diagnostics France for their trust and ongoing support. This partnership represents a unique opportunity for our biotechnology startup, and we are eager to fully embrace this chance for growth and collaboration. #biotechnology #startup #RocheDiagnostics #mentoring #collaboration #innovation #health #biotech #entrepreneurship #partnership #growth #expertise #opportunity

On February 5th, Dr. Cyril Sarrauste de Menthiere , one of our esteemed scientific advisors and patient partners, had the honor of being invited to a roundtable organized by the Paris Saclay Cancer Cluster : Why and How Work with Patients from the Earliest Stages of an Innovative Project?   He eloquently emphasized the importance for startups and pharmaceutical companies to collaborate with patient partners, using the concrete example of ReACT Therapeutics.   From its inception, the co-founders of ReACT Therapeutics, Emile Roussel, PhD, Lise Clément-Demange & Renaud VAILLANT, made the bold choice to integrate a patient partner into their scientific committee. But why?   #1 Developing a drug candidate for patients cannot be done without patients.  #2 The patient partner brings a wealth of information, firsthand experiences, and crucial insights to the startup.  #3 They participate in general meetings and can be called upon to address specific needs.  #4 The patient partner plays a key role in recruiting patients for clinical trials.  #5 They contribute to promoting the startup, its team, and its solution within their network. #PatientPartnership #HealthcareInnovation #PatientEngagement #Startups #Pharmaceuticals #CancerResearch #PatientExperience #HealthcareCollaboration #ScientificAdvisors #MedicalInnovation #ResearchPartnership #PatientAdvocacy #HealthcareNetworking #DrugDevelopment #HealthcareInsights

Une part de l écosystème #biotech grenoblois s est rendue à BioFIT Event. 2 jours riches en contacts. Des PME et start-up innovantes. J'ai été particulièrement impressionnée par les start-up Slams convaincants. #grenoblealpes #healthtech Céline BERHAULT Marie GILBERT-COLLET Valentine Panel Emile Roussel, PhD Claire Cudrey Fabienne Agasse Bruno Tillier Arnaud Peyronnier ALTHEKIA Linksium Yann de Boysson CEA-Leti ReACT Therapeutics Cézame Connexions Eurofins Optimed Clinical Research Capucine Henquell

We’ve heard them pitch their innovative project at #BioFIT2023 during the first session of the Start-up Slams in the oncology and drug discovery categories: Orakl Oncology, NASASBIOTECH SL, CasInvent Pharma, GlioCure, ReACT Therapeutics, Oncosema and Urania Therapeutics. 🙌 Many thanks to our jury members for their time and their invaluable advice: Jerome Majoie (fondation fournier majoie pour l'innovation), Emilio Erazo-Fischer (Boehringer Ingelheim) and Tugrul OZDEMIR (Novo Holdings). Marine Pentier Vincent Tavernier Aminata-Louise Soumaré Marion Loizurot 

We’ve heard them pitch their innovative project at #BioFIT2023 during the first session of the Start-up Slams in the oncology and drug discovery categories: Orakl Oncology, NASASBIOTECH SL, CasInvent Pharma, GlioCure, ReACT Therapeutics, Oncosema and Urania Therapeutics. 🙌 Many thanks to our jury members for their time and their invaluable advice: Jerome Majoie (fondation fournier majoie pour l'innovation), Emilio Erazo-Fischer (Boehringer Ingelheim) and Tugrul OZDEMIR (Novo Holdings). Marine Pentier Vincent Tavernier Aminata-Louise Soumaré Marion Loizurot